Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 7,076 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Terminated No phase listed Observational

Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer

NCT02483377
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 27, 2026, 10:40 AM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

NCT01901094
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
Axillary Lymph Node Dissection (ALND), Nodal Radiation Therapy, Axillary Radiation Therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1228
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 730 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Breast Tissue Bioavailability of Topically Applied Limonene

NCT01459172
View directory record Official record
Conditions
Breast Cancer
Interventions
limonene containing massage oil
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 27, 2026, 10:40 AM EDT
Completed Phase 2 Interventional

A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer

NCT00191672
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Gemcitabine, Paclitaxel, Docetaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Nashville, Tennessee • Katy, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 27, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Low Level Laser Treatment and Breast Cancer Related Lymphedema

NCT00852930
View directory record Official record
Conditions
Lymphedema
Interventions
laser and MLD combined, laser alone, manual lymphatic drainage
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 27, 2026, 10:40 AM EDT
Recruiting Phase 1 Interventional

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

NCT06908928
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
bulumtatug fuvedotin
Drug
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Duarte, California • La Jolla, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 27, 2026, 10:40 AM EDT
Completed No phase listed Observational

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

NCT03981705
View directory record Official record
Conditions
TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, ERany/PRany/HER2+ Breast Cancer
Interventions
Standard Trimodality Breast Imaging
Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 27, 2026, 10:40 AM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 27, 2026, 10:40 AM EDT
Completed Not applicable Interventional Results available

Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer

NCT03374995
View directory record Official record
Conditions
Breast Carcinoma, Radiation-Induced Dermatitis
Interventions
Best Practice, Quality-of-Life Assessment, Topical Keratin
Other · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 27, 2026, 10:40 AM EDT
Terminated Not applicable Interventional Results available

Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy

NCT01796977
View directory record Official record
Conditions
Breast Cancer, Reconstructive Breast Surgery
Interventions
OxyGenesys Dissolved Oxygen Dressing, Standard Gauze Dressing
Device
Lead sponsor
Halyard Health
Industry
Eligibility
21 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Chicago, Illinois • St Louis, Missouri • Great Neck, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 27, 2026, 10:40 AM EDT
Terminated Not applicable Interventional Results available

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

NCT01897441
View directory record Official record
Conditions
Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Trastuzumab, Endocrine therapy
Drug · Other · Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 27, 2026, 10:40 AM EDT
Not listed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer

NCT00114296
View directory record Official record
Conditions
Breast Cancer
Interventions
omega-3 fatty acid
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 27, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional

Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

NCT00101062
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib, letrozole
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 27, 2026, 10:40 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

NCT04215146
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Paclitaxel, Pelareorep, Avelumab
Drug · Biological
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Miami, Florida • Urbana, Illinois • Indianapolis, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 27, 2026, 10:40 AM EDT
Completed Not applicable Interventional

IIT2020-20-SHIRAZIP-WALK: Nature Walks

NCT04896580
View directory record Official record
Conditions
Breast Cancer, Cancer, Lymphoma, Leukemia, Prostate Cancer, Thyroid Cancer, Hematologic Malignancy, Non-hodgkin Lymphoma
Interventions
Nature based exercise
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 27, 2026, 10:40 AM EDT
Completed No phase listed Observational

Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine

NCT00478686
View directory record Official record
Conditions
Breast Cancer
Interventions
Phlebotomy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 27, 2026, 10:40 AM EDT
Completed No phase listed Observational

Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer

NCT01970670
View directory record Official record
Conditions
Breast - Female
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 27, 2026, 10:40 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families

NCT07542405
View directory record Official record
Conditions
BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome, BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Neoplastic Syndrome, Lynch Syndrome
Interventions
Discussion, Internet-Based Intervention, Survey Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 27, 2026, 10:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251
View directory record Official record
Conditions
Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib, Abemaciclib, Carboplatin, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:40 AM EDT
Terminated Phase 3 Interventional Results available

Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases

NCT00581113
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Prostate Cancer
Interventions
Radiotherapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 27, 2026, 10:40 AM EDT
Completed No phase listed Observational

An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu

NCT00153218
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Cancer Research Network
Other
Eligibility
Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Plantation, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 27, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Oxybutynin Chloride in Managing Hot Flashes

NCT02961790
View directory record Official record
Conditions
Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ, No Evidence of Disease
Interventions
Oxybutynin Chloride, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Peoria, Illinois • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 27, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

NCT01797120
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, Everolimus, Placebo
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
25
States / cities
Greenbrae, California • Stanford, California • Rockford, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 27, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

NCT00003782
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
5,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
146
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 27, 2026, 10:40 AM EDT